Advertisement
Screener

Zoetis Inc. (ZTS) ROI

Zoetis Inc. ROI

Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Zoetis Inc. roi for the quarter ending 2025-12-31 was 21.29%, a 2.25% decline year-over-year.
  • Zoetis Inc. roi for the quarter ending 2025-09-30 was 21.10%.
  • Zoetis Inc. roi for the quarter ending 2025-06-30 was 22.07%.
  • Zoetis Inc. roi for the quarter ending 2025-03-31 was 21.75%.
  • Zoetis Inc. roi for fiscal 2025 was 21.60%, a 1.45% decline from fiscal 2024.
  • Zoetis Inc. roi for fiscal 2024 was 21.92%, a 8.07% increase from fiscal 2023.
  • Zoetis Inc. roi for fiscal 2023 was 20.29%, a 18.08% increase from fiscal 2022.
  • Zoetis Inc. roi for fiscal 2022 was 17.18%, a 6.08% decline from fiscal 2021.
Available history
2014-12-31 to 2025-12-31
Data captured

Historical ROI

DateROINet income 12 monthNet income 3 monthDebt plus equity
2025-12-3121.29%$2.65B$603.00M$12.46B
2025-09-3021.10%$2.63B$721.00M$12.47B
2025-06-3022.07%$2.59B$726.00M$11.74B
2025-03-3121.75%$2.49B$602.00M$11.44B
2024-12-3121.78%$2.49B$581.00M$11.41B
2023-12-3120.29%$2.34B$525.00M$11.56B
2023-09-3019.61%$2.28B$596.00M$11.63B
2023-06-3019.80%$2.21B$671.00M$11.18B
2023-03-3118.74%$2.07B$552.00M$11.05B
2022-12-3117.18%$2.11B$461.00M$12.31B
2022-09-3018.42%$2.07B$529.00M$11.22B
2022-06-3018.74%$2.09B$529.00M$11.15B
2022-03-3118.45%$2.07B$595.00M$11.24B
2021-12-3118.29%$2.04B$414.00M$11.14B
2021-09-3017.58%$1.98B$552.00M$11.27B
2021-06-3016.54%$1.91B$512.00M$11.54B
2021-03-3115.73%$1.77B$559.00M$11.28B
2020-12-3114.93%$1.64B$359.00M$10.97B
2020-09-3014.71%$1.66B$479.00M$11.3B
2020-06-3015.14%$1.62B$377.00M$10.68B
2020-03-3117.48%$1.61B$423.00M$9.22B
2019-12-3116.38%$1.5B$384.00M$9.16B
2018-12-3116.55%$1.43B$345.00M$8.63B
2017-12-3112.82%$864M$81.00M$6.74B
2017-10-0112.14%$937M$298.00M$7.72B
2017-07-0214.13%$878M$247.00M$6.22B
2017-04-0214.01%$855M$238.00M$6.1B
2016-12-3113.76%$821M$154.00M$5.97B
2016-10-0211.36%$689M$239.00M$6.07B
2016-07-0310.95%$639M$224.00M$5.84B
2016-04-036.69%$378M$204.00M$5.65B
2015-12-315.69%$339M$22.00M$5.95B
2015-09-279.08%$443M$189.00M$4.88B
2015-06-288.67%$420M-$37.00M$4.85B
2015-03-2911.98%$593M$165.00M$4.95B
2014-12-3111.75%$583M$126.00M$4.96B

Annual ROI

DateROINet income 12 monthDebt plus equity
2025-12-3121.60%$2.67B$12.37B
2024-12-3121.92%$2.49B$11.34B
2023-12-3120.29%$2.34B$11.56B
2022-12-3117.18%$2.11B$12.31B
2021-12-3118.29%$2.04B$11.14B
2020-12-3114.93%$1.64B$10.97B
2019-12-3116.38%$1.5B$9.16B
2018-12-3116.55%$1.43B$8.63B
2017-12-3112.82%$864M$6.74B
2016-12-3113.76%$821M$5.97B
2015-12-315.69%$339M$5.95B
2014-12-3111.75%$583M$4.96B

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10